InnoCare Announces Estimated Annual Results for 2025

Beijing, Jan 29, 2026 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the estimated annual results for 2025 as of 31 December 2025.

Based on a preliminary estimate by the finance department, InnoCare is expected to achieve total revenue of approximately RMB2,365 million in 2025, representing a 134% increase compared to 2024. The Company is expected to turn from loss to profit for the first time in 2025, with a net profit of RMB633 million, primarily attributable to robust commercial growth and license-out revenue from business development activities.

InnoCare achieved rapid commercial growth in 2025. Orelabrutinib continued to experience strong sales growth throughout 2025. This was driven by continued expansion in marginal zone lymphoma (MZL), as well as the approval of first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Additionally, we’ve begun to commercialize tafasitamab, which was approved as the first CD19 antibody for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in China.

In 2025, InnoCare continued to advance its Stage 2.0 goals, with its core pipeline achieving the following key milestones:

• Orelabrutinib was approved for first-line treatment of CLL/SLL and included in the National Reimbursement Drug List (NRDL), and recognized as a Class I recommendation in the CSCO Guidelines for Lymphoma Diagnosis and Treatment (2025 Edition). With all four indications included in the NRDL, orelabrutinib is positioned to benefit a broader patient population. Additionally, orelabrutinib received marketing approval in Singapore for the treatment of R/R MZL.
• Tafasitamab became the first CD19 antibody approved for the treatment of R/R DLBCL in China.
• The next-generation TRK inhibitor Zurletrectinib (ICP-723) was approved for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions.
• The BCL2 inhibitor mesutoclax (ICP-248) has entered two Phase III clinical trials. Patient enrollment is nearing completion in the first-line CLL/SLL study of mesutoclax in combination with orelabrutinib, while the clinical trial in BTKi-treated mantle cell lymphoma (MCL) is progressing. Additional studies in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are ongoing across China and globally. Mesutoclax has been granted Breakthrough Therapy Designation (BTD), marking the first BCL2 inhibitor to receive BTD recognition in China.
• The novel TYK2 inhibitor soficitinib (ICP-332) has completed patient enrollment in its Phase III clinical trial for moderate-to-severe atopic dermatitis (AD) as well as the Phase II clinical trial for vitiligo. It has also entered clinical trials for prurigo nodularis, CSU and psoriasis.
• The novel TYK2 inhibitor ICP-488 is approaching completion of patient enrollment in its Phase III clinical trial for psoriasis, while the Phase II clinical trial for cutaneous lupus erythematosus (CLE) is ongoing.
• The antibody-drug conjugate (ADC) platform reached a major milestone with IND approval for the first in-house ADC candidate, ICP-B794.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.